Drug Profile
Islet cell replacement therapy - Kadimastem
Alternative Names: Beta cell therapy - Kadimastem; Encapsulin; Incapsulin; IsletRxLatest Information Update: 14 Jun 2023
Price :
$50
*
At a glance
- Originator Kadimastem
- Class Cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 14 Jun 2023 Islet cell replacement therapy is still in preclinical study for Type-1 diabetes mellitus in Israel (Parenteral, Implant) (Kadimastem pipeline, June 2023)
- 28 Feb 2023 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in Israel (Parenteral, Implant)
- 30 Sep 2022 Kadimastem receives patent for enrichment technology in Israel, Japan and Australia